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Abstract: Absence epilepsy and depression are comorbid disorders, but the molecular link between
the two disorders is unknown. Here, we examined the role of the melatoninergic system in
the pathophysiology of spike and wave discharges (SWDs) and depression-like behaviour in the
Wistar Albino Glaxo from Rijswijk (WAG/Rij) rat model of absence epilepsy. In WAG/Rij rats,
SWD incidence was higher during the dark period of the light-dark cycle, in agreement with
previous findings. However, neither pinealectomy nor melatonin administration had any effect on
SWD incidence, suggesting that the melatoninergic system was not involved in the pathophysiology
of absence-like seizures. Endogenous melatonin levels were lower in the hippocampus of WAG/Rij
rats as compared to non-epileptic control rats, and this was associated with higher levels of melatonin
receptors in the hippocampus, but not in the thalamus. In line with the reduced melatonin levels, cell
density was lower in the hippocampus of WAG/Rij rats and was further reduced by pinealectomy.
As expected, WAG/Rij rats showed an increased depression-like behaviour in the sucrose preference
and forced swim tests, as compared to non-epileptic controls. Pinealectomy abolished the difference
between the two strains of rats by enhancing depression-like behaviour in non-epileptic controls.
Melatonin replacement displayed a significant antidepressant-like effect in both WAG/Rij and control
rats. These findings suggest that a defect of hippocampal melatoninergic system may be one of
the mechanisms underlying the depression-like phenotype in WAG/Rij rats and that activation of
melatonin receptors might represent a valuable strategy in the treatment of depression associated
with absence epilepsy.
Keywords: absence seizures; pinealectomy; depression; melatonin; MT receptors
1. Introduction
The hormone melatonin possesses neuromodulatory properties, exerts inhibitory function in the
central nervous system (CNS) and regulates the circadian rhythms. The main source of melatonin in
the brain is the pineal gland. Exogenously delivered melatonin has antioxidant [1], neuroprotective [2],
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anticonvulsant [3], as well as anxiolytic effects [4,5] in rodents. Long-term treatment with this
hormone corrects disease-induced neuronal damage and behavioral disturbances in a variety of
models [6–8]. Recently, we have found that melatonin treatment before or after kainate (KA)-induced
status epilepticus (SE) exerts a strain-dependent effect on oxidative stress [9] and development of
epileptogenesis [10,11]. Melatonin treatment suppresses KA-induced seizures only during the period
of treatment in Wistar rats [10] and causes a long-lasting reduction of motor seizures in spontaneously
hypertensive rats [11].
Previous studies have shown that the removal of the pineal gland, which causes a substantial
decrease in the plasma melatonin levels, increases the seizure threshold, thereby facilitates the
development of epileptogenic processes in different seizure models [12–14]. Pinealectomy shortens
the latent seizure-free period in the pilocarpine model of temporal lobe epilepsy [12], reduces the
number of electrical stimulations of amygdala required for kindling development [13], and decreases
the latency of initial epileptiform discharges in the penicillin model of focal epilepsy [14]. In addition,
pinealectomy exacerbates pilocarpine-induced neuronal death and mossy fiber sprouting in the
hippocampus [12]. Melatonin replacement reverses the pro-convulsant effect of pinealectomy in the
pilocarpine model of SE and penicillin model of focal epilepsy [12,14]. Melatonin has shown to exert
both pro- and anticonvulsant effects in humans with intractable seizures [15,16]. There are only a
few data on the effect of melatonin on absence epilepsy. These data are limited to two articles in
which melatonin influences spike-wave discharges (SWDs) in the Wistar Albino Glaxo from Rijswijk
(WAG/Rij) rat model of absence epilepsy [17,18]. WAG/Rij rats develop SWDs associated with
behavioral arrest after 3–4 months of age, and represent a valuable model of absence epilepsy in
humans with lack of responsiveness during SWDs, their increased incidence at transitions among the
sleep phases, inheritance and effectiveness of anti-absence drug ethosuximide but not that of other
anti-convulsant drugs such as tiagabine, carbamazepine and diphenylhydantoin against SWDs [19,20].
The WAG/Rij strain does not recapitulate, however, two other aspects of absence epilepsy, the late
appearance of the SWDs during life span in rats compared to early manifestation of absence seizures in
childhood of humans; and the frequency difference of the spikes and waves in the SWD episodes [20].
Interestingly WAG/Rij rats display a depression-like phenotype [21], and therefore can be also used
for study of mechanisms underlying the established comorbidity between absence epilepsy and
depression in absence epilepsy [22,23]. This gave us impetus to study the effects of pinealectomy and
melatonin replacement in WAG/Rij rats because the suprachiasmatic/pineal gland/melatonin axis is
critically involved in the pathophysiology of mood disorders and sleep abnormalities associated with
these disorders.
We now report that the manipulation of the melatonin axis has no impact on the incidence and the
circadian periodicity of absence seizures in WAG/Rij rats, but has a profound effect on depression-like
behavior in these animals. In addition, we show that the hippocampal melatoninergic system is
abnormal in WAG/Rij rats, and this may provide a potential link between absence seizures and
comorbid depression-like phenotype.
2. Results
2.1. Melatonin Had No Role in the Circadian Rhythm of Absence Seizures and No Impact on their Incidence in
WAG/Rij Rats
The electrographic profile of SWDs and the dynamics of the hourly percent time (PT, time spent
in SWDs in percent) over 24 h in WAG/Rij rats are shown in Figure 1A,B.
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Figure 1. Effects of pinealectomy and melatonin treatment on SWDs in Wistar Albino Glaxo from 
Rijswijk (WAG/Rij) rats. Representative SWD and PT in SWDs per hour of recording from 6:00 a.m. 
(light on) to 6:00 p.m. (light off) in Sham and pinealectomized (Pin) WAG/Rij rats are shown in (A,B), 
respectively. Total PT in SWDs during the entire light and dark phases is shown in the inset. (§)—
Significant difference between light and dark phases for both Pin and Sham rats [2-way ANOVA and 
post-hoc Fisher least-significant difference (LSD) test, p < 0.05]. The effects of treatment with 
melatonin (80 mg·kg−1 s.c.) and vehicle in Sham and Pin rats on PT in SWDs are shown in (C). 
Injections were performed at 10:00 p.m. (arrow in (C-a)). SWDs were counted from the second 30-min 
period after injections to minimize the effect of stress on the incidence of SWDs. Total PTs in SWDs 
in the 4 h preceding and following vehicle or melatonin treatments in Sham and Pin rats are shown 
in (C-b) and (C-c), respectively. Values are means ± S.E.M. 
Two-way analysis of variance with repeated measures (rANOVA) showed significant effect of 
light-dark Phase [F(1,5) = 15.51, p = 0.011], as well as Phase x Hour interaction [F(11,55) = 2.27, p = 0.023] 
on PT in SWDs for the 12-h duration of light and dark phases in intact WAG/Rij rats. The acrophase 
of SWD incidence was between 11:00 p.m. and 0:00 a.m. Total PT in SWDs during dark was 
Figure 1. Effects of pinealectomy and melatonin treatment on SWDs in Wistar Albino Glaxo from
Rijswijk (WAG/Rij) rats. Representative SWD and PT in SWDs per hour of recording from 6:00 a.m.
(light on) to 6:00 p.m. (light off) in Sham and pinealectomized (Pin) WAG/Rij rats are shown in
(A,B), respectively. Total PT in SWDs during the entire light and dark phases is shown in the inset.
(§)—Significant difference between light and dark phases for both Pin and Sham rats [2-way ANOVA
and post-hoc Fisher least-significant difference (LSD) test, p < 0.05]. The effects of treatment with
melatonin (80 mg·kg−1 s.c.) and vehicle in Sham and Pin rats on PT in SWDs are shown in (C).
Injections were performed at 10:00 p.m. (arrow in (C-a)). SWDs were counted from the second 30-min
period after injections to minimize the effect of stress on the incidence of SWDs. Total PTs in SWDs in
the 4 h preceding and following vehicle or melatonin treatments in Sham and Pin rats are shown in
(C-b) and (C-c), respectively. Values are means ± S.E.M.
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Two-way analysis of variance with repeated measures (rANOVA) showed significant effect of
light-dark Phase [F(1,5) = 15.51, p = 0.011], as well as Phase x Hour interaction [F(11,55) = 2.27, p = 0.023]
on PT in SWDs for the 12-h duration of light and dark phases in intact WAG/Rij rats. The acrophase of
SWD incidence was between 11:00 p.m. and 0:00 a.m. Total PT in SWDs during dark was approximately
two-fold higher than during light: 26.08 ± 4.85% and 12.53 ± 2.37%, respectively (Figure 1B, inset).
Pinealectomy did not affect the PT in SWDs both during the dark and light phases: [F(1,8) = 0.28,
p = 0.61]. Melatonin administered just before the acrophase (at 10:00 p.m.) did not affect PT in SWDs
neither in pinealectomized WAG/Rij rats nor in rats without pinealectomy (Sham) (Figure 1C-a).
Three-way repeated measure analysis of variance (rANOVA) did not demonstrate main effects of
Group (Sham, Pin), Drug (mel, veh) and Time (each 0.5 h epoch). Post-hoc comparisons did not reveal
any significant difference between total PTs in SWDs in 4 h before and 4 h after melatonin injection,
neither between Sham and Pin rats, nor between vehicle and melatonin injections in both groups
(Figure 1C-b,C-c). Taken together these data suggest that melatonin has no major role in the increased
PT in SWDs observed during the dark phase in WAG/Rij rats.
2.2. Abnormalities in Hippocampal Melatonergic System in WAG/Rij Rats
Endogenous melatonin levels were largely reduced in the hippocampus of WAG/Rij rats, as
compared to age-matched non-epileptic Wistar rats. Melatonin levels in intact WAG/Rij rats were
as lower as levels observed in pinealectomized Wistar rats (95%↓) (Figure 2A). The estimated effect
size [24] (coefficient Cohen’s d = 0.94, percent overlap (OL) = 46%) showed that 54% of WAG/Rij
rats were reliably sensitive to the reduction of the melatonin level in hippocampus versus 46% of
Wistar rats. Pinealectomy largely reduced melatonin levels in Wistar rats but had only small effects in
WAG/Rij rats. Subcutaneous melatonin replacement after pinealectomy (10 mg/kg, once a day for
18 days) raised hippocampal melatonin levels in both strains of rats, but not to the extent found in the
intact Wistar rats.
We also compared the expressions of the MT receptors in the hippocampus of Wistar and WAG/Rij
rats. As compared to Wistar rats, WAG/Rij rats showed higher MT1 (128%↑, Cohen’s d = 3.4, OL = 5%)
and MT2 (182%↑, Cohen’s d = 3.8, OL = 3%) receptor protein levels in the hippocampus (Figure 2B).
There was a trend for pinealectomy to increase the hippocampal levels of MT1 and MT2 receptor protein
levels in both strains of rats, Wistar and WAG/Rij (p values between 0.05 and 0.1). The additional
analysis of the effect sizes (Cohen’s d coefficients and percent OL, [24]) showed, however, that the
increase in the hippocampal MT1 receptor levels with 45%↑ (Cohen’s d = 2.2, OL = 16%) obtained in
84% of pinealectomized WAG/Rij rats, and the increase in the MT2 receptor levels with 143%↑ (d = 1.8,
OL = 23%) obtained in 77% of the same WAG/Rij rats differed substantially from the corresponding
values obtained in sham rats (16% and 23%). We extended the analysis to the ventrobasal thalamus,
which is a key region in the cortico-thalamic-cortical network involved in SWDs [25]. We did not find
significant difference between Wistar and WAG/Rij rats for both MT1 and MT2 receptor expressions
in the ventrobasal complex of thalamus (Figure 2E).
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Figure 2. Changes in hippocampal melatonin and levels of MT1 and MT2 protein receptor levels in 
WAG/Rij rats. (A) Hippocampal levels of melatonin in Wistar and WAG/Rij rats under basal 
conditions (Sham), 24 days after surgical removal of the pineal gland (Pin), and after melatonin 
replacement (10 mg/kg, s.c., daily for 18 days, administered at 5.30 p.m.). (#) p < 0.05 between intact 
WAG/Rij and Wistar rats; (B) Western blot analysis of MT1 and MT2 receptors in the hippocampus 
of Wistar and WAG/Rij rats. (#) p < 0.05 between WAG/Rij and Wistar rats; (C) Effect of pinealectomy 
on hippocampal MT1 and MT2 receptor levels in Wistar rats and the representative Western blots on 
the left; (D) Effect of pinealectomy on hippocampal MT1 and MT2 receptor levels in WAG/Rij rats 
and the representative Western blots on the left; (E) Western blot analysis of MT1 and MT2 receptor 
protein levels in the ventrobasal thalamus of Wistar and WAG/Rij rats. All values are means + S.E.M. 
Statistical analysis was performed using the Mann–Whitney U test. 
2.3. Reduced Hippocampal Cell Density in WAG/Rij Rats 
Knowing that the lack of melatonin causes cell death in the hippocampus [26,27], we counted 
cell number after Nissl staining in WAG/Rij and non-epileptic Wistar rats. Interestingly, cell density 
was significantly reduced in three hippocampal subregions (CA1, CA3, and Hilus) of WAG/Rij rats 
compared to that in Wistar rats (Figure 3), as follows: CA1 (25%↓ , d = 6.4, OL = 2%); CA3 (9%↓ , d = 
2.3, OL = 14%); Hilus (22%↓ , d = 3.9, OL = 2.6%). The coefficients Cohen’s d and percent overlaps 
Figure 2. hanges in hippoca pal elatonin and levels of T1 and T2 protein receptor levels in
/Rij rats. (A) Hippocampal levels of melatonin in Wistar and WAG/Rij rats under basal conditions
(Sham), 24 days after surgical removal of the pineal gland (Pin), and after melatonin replacement
(10 mg/kg, s.c., daily for 18 days, administered at 5.30 p.m.). (#) p < 0.05 between intact WAG/Rij
and Wistar rats; (B) Western blot analysis of MT1 and T2 receptors in the hippocampus of Wistar
and WAG/Rij rats. (#) p < 0.05 between WAG/Rij and Wistar rats; (C) Effect of pinealectomy on
hippocampal MT1 and MT2 receptor levels in Wistar rats and the representative Western blots on
the left; (D) Effect of pinealectomy on hippocampal MT1 and MT2 receptor levels in WAG/Rij rats
and the representative Western blots on the left; (E) Western blot analysis of MT1 and MT2 receptor
protein levels in the ventrobasal thalamus of Wistar and WAG/Rij rats. All values are means + S.E.M.
Statistical analysis was performed using the Mann–Whitney U test.
2.3. educed ippoca pal ell ensity in / ij ats
no ing that the lack of elatonin ca ses cell eath in the hi oca s [26,27], e co nte
cell n ber after issl staining in ij an non-e ile tic istar rats. Interestingly, cell ensity
as significantly re ce in three hi oca al s bregions ( 1, 3, an il s) of AG/ ij rats
co pare to that in istar rats (Figure 3), as follows: CA1 (25%↓, d = 6.4, OL = 2%); CA3 (9%↓, d = 2.3,
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OL = 14%); Hilus (22%↓, d = 3.9, OL = 2.6%). The coefficients Cohen’s d and percent overlaps (OL)
calculated according to [24] showed that more than 86% of WAG/Rij rats were reliably sensitive to
the cell loss in these three hippocampal fields versus only 14% of Wistar rats. Pinealectomy further
decreased hippocampal cell density in WAG/Rij rats (Figure 3): CA1 (45%↓, d = 2.4, OL = 13%); CA3
(25%↓, d = 2.0, OL = 19%); and Hilus (36%↓, d = 1.8, OL = 23%), which means that more than 77% of
Pin rats had cell density loss in hippocampus not obtained in Sham rats, and these effects might be
interpreted as large [24].
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Figure 3. Cell density in the hippocampus of Wistar and WAG/Rij rats, and effects of pinealectomy in 
WAG/Rij rats. Representative Nissl-stained sections of CA1, CA3 and Hilus are shown on the left. 
Scale bars: 200 µm for 10× and 20 µm for 60×. Values of cell densities are means ± S.E.M. for Wistar-
Naive; WAG/Rij-Sham, and WAG/Rij-Pin. p < 0.05 between intact WAG/Rij and Wistar rats (#), or 
between WAG/Rij-Pin versus WAG/Rij-Sham rats (*). Statistical analysis was performed with the 
Mann–Whitney U test. 
2.4. Influence of Melatonin on Depression-Like Behavior in WAG/Rij and Non-Epileptic Wistar Rats 
For the analysis of depression-like behavior, we used two behavioral tests: (i) the saccharine 
preference test (SPT) for assessment of anhedonia; and (ii) the forced swim test (FST) as a despair-
like behavior. As expected, WAG/Rij rats showed an increase in depressive-like behavior (less 
preference to saccharine solution in SPT (41%↓ , d = 1.8, OL = 23%) and greater immobility time in 
i re 3. Cell density in the hi pocampus of Wistar and WAG/Rij rats, and effects of pinealectomy
in WAG/Rij rats. Representative Nissl-stained sections of CA1, CA3 and Hilus are shown on the
left. Scale bars: 200 µm for 10× and 20 µm for 60×. Values of cell densities are means ± S.E.M. for
Wistar-Naive; WAG/Rij-Sham, and WAG/Rij-Pin. p < 0.05 between intact WAG/Rij and Wistar rats (#),
or between WAG/Rij-Pin versus WAG/Rij-Sham rats (*). Statistical analysis was performed with the
ann– hitney U test.
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2.4. Influence of Melatonin on Depression-Like Behavior in WAG/Rij and Non-Epileptic Wistar Rats
For the analysis of depression-like behavior, we used two behavioral tests: (i) the saccharine
preference test (SPT) for assessment of anhedonia; and (ii) the forced swim test (FST) as a despair-like
behavior. As expected, WAG/Rij rats showed an increase in depressive-like behavior (less preference to
saccharine solution in SPT (41%↓, d = 1.8, OL = 23%) and greater immobility time in FST as compared
to Wistar rats (22%↑, d = 1.0, OL = 45%) (Figure 4). The d coefficients of Cohen and percent OLs
showed that more than 77% of WAG/Rij rats had decreased preference in SPT and more than 55% of
them had increased immobility time not obtained by Wistar rats.
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Figure 4. Depression-like behavior in Wistar and WAG/Rij rats. Effects of strain (WAG/Rij and Wistar 
rats), pinealectomy (Sham and Pin rats) and drug (sub-chronic 18-day-treatment with melatonin, 10 
mg·kg−1 s.c. or its vehicle) on saccharine preference in the SPT and immobility time in the FST are 
shown in (A,B), respectively. (#) p < 0.05 (Student’s t test) between Wistar and WAG/Rij rats; (*) p < 
0.05 between Sham and Pin rats, treated with vehicle (two-way ANOVA (Strain and Pinealectomy) 
and Fisher LSD test); (+) p < 0.05 between vehicle-treated and melatonin-treated Pin rats (two-way 
ANOVA (Strain and Drug) and Fisher LSD test). Values are means ± S.E.M. 
Pinealectomy abolished the difference between Wistar and WAG/Rij rats in both behavioral tests 
by increasing the depression-like behavior in Wistar rats (less preference 35%↓ , d = 2.5, OL = 12% in 
SPT and 33%↑ , d = 1.7, OL = 25% in FST in Wistar rats with pinealectomy vs. sham Wistar rats). 
Pinealectomy did not change sucrose preference but slightly increase the immobility time (18%↑ , d 
= 0.9, OL = 48.4%) in WAG/Rij rats. Two-way ANOVA revealed a significant effect of Strain [F(1,48) = 
8.19, p = 0.006] and pinealectomy [F(1,48) = 4.09, p = 0.04] (Figure 4A). Melatonin replacement after 
pinealectomy for 18 days caused a substantial antidepressant-like effect in the SPT in both Wistar 
(31%↑ , d = 1.5, OL = 29%) and WAG/Rij (31%↑ , d = 1.2, OL = 38%) rats [F(1,33) = 10.19, p = 0.003] 
(Figure 4A). Sub-chronic treatment with melatonin produced significant antidepressant effects also 
in the FST for both Wistar (30%↓ , d = 1.6, OL = 27%) and WAG/Rij rats (31%↓ , d = 1.6, OL = 27%) 
[two-way ANOVA: F(1,45) = 29.12, p < 0.000001] (Figure 4B). The d coefficients of Cohen and percent of 
OL showed that the effects of melatonin substitution might be classified as large according the 
Cohen’s standard (see [24]). 
3. Discussion 
Clinical studies indicate that epilepsy and depression are comorbid disorders in both children 
and adults, and comorbidity is also found in patients affected by genetic generalized epilepsies, such 
as juvenile myoclonic epilepsy and absence epilepsy [28–32]. The cause-to-effect relationship between 
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for the comorbidity, remains to be determined. WAG/Rij rats, which develop age-dependent, 
spontaneous absence seizures, have been described as a genetic animal model of absence epilepsy 
and mild comorbid depression [33]. These animals show decreased investigative activity in the open 
field, increased immobility in the FST, and reduced sucrose preference in the SPT [33,34], also found 
in the present study. Using the WAG/Rij model, Russo and co-workers [34] have demonstrated that 
the atypical antipsychotic aripiprazole, improves depression-like behavior and cognitive functions 
associated with absence epilepsy, a finding of potential translational value for drug treatment in 
humans. Understanding why WAG/Rij rats exhibit a mild depression-like phenotype might shed 
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adults, and comorbidity is als found in patients affected by genetic generalized epilepsies,
such as juvenile myoclonic epilepsy and absence epilepsy [28–32]. The cause-to-effect relationship
b tween depression a d absence or convulsiv epilepsy is uncertai , and w ther th re is a
tr te for both phenotypes or, rather, psychos cial or iatrogenic factors account for
the comorbidity, remains to be determined. WAG/Rij rats, which develop age-dependent, spontaneous
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absence seizures, have been described as a genetic animal model of absence epilepsy and mild
comorbid depression [33]. These animals show decreased investigative activity in the open field,
increased immobility in the FST, and reduced sucrose preference in the SPT [33,34], also found in
the present study. Using the WAG/Rij model, Russo and co-workers [34] have demonstrated that
the atypical antipsychotic aripiprazole, improves depression-like behavior and cognitive functions
associated with absence epilepsy, a finding of potential translational value for drug treatment in
humans. Understanding why WAG/Rij rats exhibit a mild depression-like phenotype might shed new
light into the biological link between absence seizures and mood disorders.
In agreement with previous findings [35], we found here that SWDs in WAG/Rij rats were more
frequent during dark (see Figure 1). We did not examine whether and how the rest activity-sleep state
influences frequency of seizures appearance in WAG/Rij rats, but it is known that the inactive state
in nocturnal rodents positively associates with absence seizures, with SWDs being more numerous
during passive waking, during the first stage of the slow-wave sleep, and at transitions among the
sleep phases [19]. In contrast, convulsive seizures show an opposite circadian rhythmicity, with
limbic seizures being more frequent during light in both rats and humans [36,37]. Although the exact
mechanism responsible for the periodicity of absence seizures remains unknown, it was reasonable to
hypothesize an involvement of the suprachiasmatic nucleus/pineal gland axis because melatonin is
secreted during dark in all animal species [38]. However, at least in our study, neither pinealectomy
nor melatonin replacement during dark had any effect on SWDs in WAG/Rij rats. The lack of effects
of pinealectomy and melatonin administration on SWDs in our study was unexpected because it has
been reported that melatonin reduces the incidence of SWDs in intact (non-pinealectomized) WAG/Rij
rats [17,18]. The reasons for these contrasting findings are unknown. At least in our WAG/Rij rats,
melatonin does not seem to have a role in the generation, incidence, and circadian pattern of absence
seizures. In addition, expression of MT1 and MT2 melatonin receptors in the thalamus did not differ
between WAG/Rij rats and age-matched non-epileptic controls.
We were surprised to find that hippocampal melatonin levels in WAG/Rij rats were reduced to an
extent similar to that observed in pinealectomized Wistar rats, and, perhaps as a consequence of this,
MT1 and MT2 receptors were up-regulated in the hippocampus of WAG/Rij rats. We could not measure
blood melatonin in WAG/Rij rats, and, therefore, we do not know whether the decrease in hippocampal
melatonin levels was due to a reduced activity of the pineal gland, to an accelerated melatonin clearance,
or to a reduced local production of melatonin in the hippocampus. An extrapineal production of
melatonin has been demonstrated in many organs, including the brain, and melatonin-synthesizing
enzymes are present in different brain structures [39]. However, the large reduction in hippocampal
melatonin levels after pinealectomy in non-epileptic Wistar rats suggested that the pineal gland was
a major, if not unique, source for hippocampal melatonin. It will be interesting to examine whether
changes in melatonin levels are also present (or not) in other brain regions of WAG/Rij rats.
We and others have found that pinealectomy causes cell death in the hippocampus, and cells
are rescued by melatonin replacement [26,27]. In line with the large reduction of local melatonin
levels, WAG/Rij rats showed a reduced cell density in the hippocampus. This supports the view
that neurons in the dorsal hippocampus are highly sensitive to the pro-survival and neurotrophic
activity of melatonin [10]. In WAG/Rij rats, pinealectomy further decreased hippocampal cell
density, although it caused only a small trend to a reduction in melatonin levels. One possible
explanation is that there were additional mechanisms by which pinealectomy caused hippocampal
cell death. For example, pinealectomy disrupts the physiological balance between melatonin and
the hypothalamic-pituitary-adrenal (HPA) axis, resulting in an uncontrolled secretion and activity of
glucocorticoids (corticosterone in rats) [27,40,41], which, in turn, might contribute to hippocampal cell
death [42,43]. This interesting hypothesis warrants further investigation.
It was logical to examine whether abnormalities in hippocampal melatoninergic system
could be related to the depression-like phenotype of WAG/Rij rats. In agreement with previous
findings [33], our WAG/Rij rats showed a reduced sucrose preference in the saccharine preference
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test and an increased immobility time in the forced swim test. Both tests have pharmacological
validity and are used for the screening of antidepressant medication (reviewed by [33]). The large
difference in hippocampal melatonin levels between WAG/Rij and non-epileptic control rats
precluded any comparison between the two strains of rats in response to a fixed dose of exogenous
melatonin. Thus, we decided to circumvent the obstacle by examining the effect of pinealectomy on
depression-like behavior in epileptic and non-epileptic rats. Interestingly, pinealectomy abolished any
difference between WAG/Rij and Wistar rats. This was due to a pro-depressant effect of pinealectomy
in non-epileptic Wistar rats. In WAG/Rij rats, pinealectomy did not further reduce sucrose preference
and only slightly enhanced the immobility time in the FST. The lack of significant behavioral effects of
pinealectomy in WAG/Rij rats was expected because these rats already showed very low melatonin
levels in the hippocampus. Melatonin treatment caused an antidepressant-like effect in both WAG/Rij
and Wistar rats after pinealectomy, i.e., in a condition in which hippocampal melatonin levels were
similar in both strain of rats.
Abnormalities of serotonergic and dopaminergic transmission are central in the pathophysiology
of depressive disorders [31,44,45]. The despair-like state in the FST is associated with abnormalities
in the reciprocal connections between dorsal raphe nucleus (the major source of forebrain serotonin)
and the prefrontal cortex, whereas anhedonia in the SPT reflects a defective activity in the mesolimbic
dopaminergic system projecting from the ventral tegmental area to the nucleus accumbens [46].
Alterations in serotonergic and dopaminergic neurotransmission have also been related to comorbidity
between absence seizures and depression in WAG/Rij rats [33]. A defective melatoninergic system
might contribute to these changes because melatonin modulates serotonin synthesis and the activity of
serotonergic neurons in the brain [47–49].
In conclusion, our findings demonstrate that, at least in the WAG/Rij model of absence epilepsy,
melatonin is not involved in the incidence or circadian pattern of SWDs, but, rather, may link the
epileptic phenotype to comorbid depression. A defective hippocampal melatoninergic system may
well account for the depression-like behavioral phenotype of WAG/Rij rats. Whether this defect
extends to other brain regions that are critically involved in the pathophysiology of mood disorders
remains to be determined. An important question is whether the reduction in hippocampal melatonin
levels in WAG/Rij rats is secondary to SWDs, or, rather, this is a primary defect that could be
genetically determined. Studies with antiabsence drugs are needed to clarify this issue. Our data lay
the groundwork for further preclinical studies aimed at establishing whether treatment with melatonin
or other agonists of MT receptors (e.g., the antidepressant agomelatine) is particularly effective in the
management of depression associated with absence epilepsy.
4. Materials and Methods
The experimental protocol was approved by the Ethical Committee of Neuromed I.R.C.C.S.
(Pozzilli, Italy) and by the Italian Ministry of Health (n. 1088/2015-PR, 19 Oct. 2015).
4.1. Animals
The experiments were performed on male inbred WAG/Rij rats (five/six-month old) and
age-matched Wistar rats housed in the animal facility of I.R.C.C.S. Neuromed Institute (Pozzilli, Italy).
The animals were housed (3–4 per cage) under standardized conditions (20 ± 3 ◦C, 40–50% humidity;
12/12-h light/dark cycle, with light on at 6:00 a.m.) and habituated for a week before experiments.
Food and water were available ad libitum throughout the study except during test procedures.
The experimental protocol with number of animals participating in each experiment is shown in
Scheme 1.
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(acute experiment) and at a dose of 10 mg·kg−1 for 18 days (subchronic experiment) just before dark,
at 5:30 p.m. These doses have previously been shown to be effective in different seizure tests [10,50].
The matched groups received vehicle in the same conditions.
4.3. Pinealectomy
Pinealectomy (Pin) was performed following the method described by Hoffmann and Reiter [51]
and used in our previous work [26]. Briefly, rats were anesthetized with isoflurane and fixed in a
stereotaxic apparatus. A piece of skull was removed at the juncture of lambda and the sagittal suture
lines. Then the pineal gland was grasped with fine forceps and removed. In sham-operated rats
(Sham), the same procedure was used except that the pineal gland was not removed.
4.4. Implantation of Electrodes and Recording and Analysis of SWDs
The implantation of the electrodes was made four-five weeks after the pinealectomy. Two pieces
of teflon (PFA)-coated stainless-steel wires (A-M Systems, Sequim, WA, USA) with diameter of
127.0 (bare)/203.2 (coated) µm were inserted into the frontal cortex through small holes in the skull
made over homologous points of both hemispheres: 0.5 mm anterioposterior to Bregma, 2.5 mm
mediolateral and 1.0–1.4 mm dorsoventral below the dura mater. The wires were cut at the desired
length immediately before the insertion without removing the PFA coating at the end and thus the
contact area for the electrosubcorticogram (ESCoG) recording was the area of the cross section of the
bare wire (area approximately 0.01 mm2). For simplicity, the ESCoG will be referred in the paper as
electroencephalogram (EEG). Two stainless steel screws (0–80 × 3/32, Plastics One) fixed above the
frontal sinus served as indifferent and ground electrodes, and also for fixing the implant to the skull.
The electrodes were connected to a miniature 6-way male socket (RS components) and the whole
assembly was fixed to the skull with Glass ionomer cement (KetacTM Cem radiopaque). The EEG
recordings began at least one week after the electrode implantation and were carried out 24 h (WAG/Rij
non-treated rats) or 12 h during the dark phase (WAG/Rij rats, treated with melatonin or its vehicle).
EEG was recorded by means of Grass-Technologies 800Hz amplifier and Grass-Telefactor software
(Astro-Med, Inc., West Warwick, RI, USA.). The beginning and the end of each SWD episode in the
EEG were determined using classical criteria [19] by means of Acknowledge 4.1.1 software (BIOPAC
Systems, Inc., Goleta, CA, USA) with a precision of 10 ms. Then, number and mean duration of SWDs
in each EEG epoch were calculated in Excel of Microsoft Office (2016). Simultaneous video-recording
of behavior was performed as additional criteria for the SWD identification [19]. The PT in SWDs was
determined in percent of the time occupied by SWDs in each epoch of EEG (1 h for the 24 h-recordings
in non-treated rats and 0.5 h for the 12 h-recordings during dark in rats treated with melatonin/vehicle).
The absolute value of PT in SWD was equal to the total number of SWDs in a given period of EEG
recording multiplied by the seconds of their mean duration in the same period. The PT in SWD was
evaluated in dynamics for each EEG epoch (1 h or 0.5 h) or as a total value for the whole EEG period of
interest (12 h of light/dark phases or 4 h before/4 h after acute treatment with melatonin or its vehicle).
4.5. Measurements of Melatonin
Hippocampal melatonin levels were quantitated after an extraction procedure with chloroform.
Hippocampi were dissected out and homogenized in RIPA buffer. An aliquot was used for protein
determination. Five hundred µL of homogenate were centrifuged in a microfuge at maximal speed for
10 and the supernatant was mixed with 2.5 mL of chloroform. The mixture was vortexed, centrifuged
(3000 rpm, 10 min), and the aqueous phase aspirated. The organic phase was separated and cleaned
once with 500 µL 0.1 N NaOH. After stirring and centrifugation (3000 rpm, 10 min), the aqueous
phase was aspirated and the organic layer was evaporated to dryness overnight at room temperature.
The residue was dissolved in 100 µL of mobile phase and centrifuged in a microfuge at maximal speed
for 15 min. Twenty µL of the supernatant were injected into the HPLC system.
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The HPLC apparatus consisted of a programmable solvent module 126 (Beckman Instrument,
Fullerton, CA, USA), an analytical C-18 reverse phase column (Ultrasphere ODS 3 µm Spherical, 80 Å
pore, 4.6 mm × 75 mm, Beckman Instrument) and a RF-551 spectrofluorometric detector (Shimadzu,
Kyoto, Japan). Excitation and emission wavelengths were set at 285 and 360 nm, respectively.
The mobile phase consisted of 85 mM acetic acetate, 0.1 mM EDTA-Na2, and acetonitrile 14% of
final volume, pH adjusted to 4.7. All analyses were performed at room temperature at an isocratic flow
rate of 1.0 mL/min. Acquisition and integration of chromatograms was performed using the Gold
Nouveau software (Beckman Instrument). The identity of melatonin peak was confirmed by spiking
with an authentic standard solution of melatonin.
4.6. Western Blotting of Melatonin Receptors
The expression of melatonin receptors MT1 and MT2 was estimated by Western blotting, using
highly specific polyclonal antibodies (1:2000, for MT1, or 1:500, for MT2, Alomone, Jerusalem, Israel)
detect bands of approximately 40 kDa, at expected molecular weight. Hippocampus and ventrobasal
complex of thalamus from Wistar and WAG/Rij rats were homogenized at 4 ◦C in 50 mM Tris-HCl
buffer, pH 7.4, containing 1 mM EDTA, 1% Triton X-100, 1 mM PMSF, 1 µg/mL aprotinin, 1 µg/mL
pepstatin, and 1 µg/mL leupeptin. After sonication, 2 µL of total extracts were used for protein
determinations. One hundred µg of protein extract were resuspended in sodium dodecyl sulfate
(SDS)-bromophenol blue reducing buffer with 40 mM dithiothreitol (DTT). Western blot analyses
were carried out by loading 35 µg of total proteins per lane into 10% SDS polyacrylamide gels, which
were electroblotted on immunoblot polyvinylidene difluoride (PVDF) membranes (BioRad, Milano,
Italy). The PVDF membranes were blocked in TBS-T buffer containing 0.25% non-fat dry milk, by
using the SNAP i.d. protein detection system (Millipore, Burlington, MA, USA), and incubated
with polyclonal MT1 or MT2 antibodies; blots were then incubated with secondary antibodies
(peroxidase-coupled anti-rabbit; 1:2000; Calbiochem, San Diego, CA, USA). Immunostaining was
revealed by enhanced chemiluminescence luminosity (GE Healthcare, Milan, Italy). The blots were
reprobed with a mouse monoclonal antibody to label β-actin (1:100.000, Sigma, St. Louis, MO, USA) or
a rabbit polyclonal GAPDH antibody (1:2.500, Abcam, Cambridge, UK) followed by an anti-mouse
secondary antibody or an anti-rabbit secondary antibody (1:7000; Calbiochem, San Diego, CA, USA),
respectively. Immunoreactive protein bands were quantified using the densitometric method (Scion
image software, http://rsb.info.nih.gov/nihimage/). Values were obtained by calculating the ratio
between the area under the curve (AUC) of the optical density of MT1 or MT2 signal and the AUC of
the house keeping protein for each lane.
4.7. Histology
Three months after pinealectomy the animals were deeply anesthetized with isoflurane and
sacrificed. Brains were fixed in Carnoy’s solution and embedded in paraffin. Portion of brain included
between 1.3 and 6.0 mm posterior from Bregma was sectioned at 10 µm. Sections regularly spaced every
350 µm were deparaffinized and processed for staining with thionin (Nissl staining for histological
assessment of neuronal degeneration). Cell density values (number of cells/mm2) were calculated.
Cells were counted within a square known as disector (40 × 40) µm for CA1, CA3, and hilus region
of hippocampus. Disectors were randomly placed by a software (Image Pro Plus 6.2) within areas
of interest, drawn by the operator. The operator detected and counted all cells within each disector.
The results were expressed as cell density/mm2.
4.8. Behavioral Tests
4.8.1. Saccharine Preference Test (SPT)
The test was performed as described previously [27]. The rats were placed in individual cages
and were supplied with two 100-mL graduated bottles; one filled with water and the other with 1%
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saccharine. The test was conducted during the dark phase. Saccharine preference was expressed as a
percentage of the volume of saccharine solution of the total volume of fluid (saccharine plus regular
water) consumed during 12-h period.
4.8.2. Forced Swim Test (FST)
A modified FST was performed according to Mazarati et al. [52]. The test was carried out in a clear
and a transparent cylinder (50 cm tall, 25 cm diameter) to a level of 30 cm from the bottom with 24 ◦C
tap water. A single 5-min swimming session was conducted and video-recorded for off-line analysis.
The parameter measured was time of immobility (in seconds) when the rat remained motionless or
made only movements necessary to keep its head above the water.
4.9. Statistical Analysis
Prior to statistical analyses, all data were inspected for outliers and normality to ensure their
appropriateness for parametric statistical tests. Both parametric and nonparametric tests were used,
depending on variables analyzed. Statistica 7.0 (Statsoft, Inc., Tulsa, OK, USA) statistical package
was used for the analysis of all data. The EEG data were analyzed using parametric statistical
evaluation with two- or three-way repeated measures rANOVAs. If there were statistical effects of
factors Pinealectomy (Sham, Pin), Phase (light, dark), Drug (vehicle, melatonin) and Time (each EEG
epoch), post-hoc analysis with Fisher LSD. The behavioral data were analyzed by 2-way ANOVA with
factors: Strain (Wistar and WAG/Rij) and Pinealectomy (Sham, Pin), and a second 2-way ANOVA
with factors Strain (Wistar and WAG/Rij) and Drug (Vehicle and Melatonin), followed by Fisher LSD
test. The difference between WAG/Rij and Wistar rats (Sham, vehicle-treated) was assessed using
Student’s t-test. The histological, the HPLC, and Western blot densitometric data were analyzed with
nonparametric Mann-Whitney U test. The significant level was set at 0.05. Additionally, percent
changes were calculated and effect sizes estimated by means of the Cohen’s d coefficients (Site of
the Social Science Statistics assessed on 24 June 2018: http://www.socscistatistics.com/effectsize/
Default3.aspx.) The percent overlaps were determined and interpreted according to [24,53].
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Abbreviations
ANOVA Analysis of variance
AUC Area under the curve
CNS Central nervous system
EEG Electroencephalogram
ESCoG Electrosubcorticogram
FST Forced swim test
HPA Hypothalamic-pituitary-adrenal axis
HPLC High performance liquid chromatography
KA Kainic acid (kainate)
LSD Least significant difference
Mel Melatonin
MT Melatonin receptor
Pin Pinealectomy (rats with removed pineal gland)
PT in SWDs Percent time in SWDs
rANOVA Repeated measure analysis of variance
OL Percent overlap
s.c. Subcutaneous
SE Status epilepticus
S.E.M. Standard error of mean
Sham Sham-operated (rats without removed pineal gland)
SPT Saccharine preference test
SWD Spike-wave discharge
WAG/Rij Wistar Albino Glaxo from Rijswijk rats
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